human fibrinogen  (Thermo Fisher)

Journal: Science Advances

Article Title: Hemostatic B-knob–triggered microgels (BK-TriGs) to address bleeding in neonates

doi: 10.1126/sciadv.ady7698

Figure Lengend Snippet: ( A ) Schematic representation of the experimental timeline: neonatal fibrinogen injection, followed by microparticle injection, liver laceration, and subsequent blood loss monitoring over 10 min. ( B ) Time course of blood loss (grams of blood per gram of animal weight) in mice treated with saline or varying doses of BK-TriGs (10, 15, and 20 mg/kg), demonstrating dose-dependent hemostatic effects. ( C ) Total blood loss analysis showing significant reduction with BK-TriGs at 15 mg/kg compared to saline ( P < 0.001) and highlighting increased blood loss at 20 mg/kg ( P < 0.0001). ( D ) Comparative blood loss over time for mice treated with NB-ULCs, AK-ULCs, and BK-TriGs at 15 mg/kg, showing superior performance of BK-TriGs. ( E ) Total blood loss for the different particle treatments, indicating the significant efficacy of BK-TriGs ( P < 0.05) compared to other groups. Data are presented as the means ± SD.

Article Snippet: In each 50-μl reaction, 45.25 μl of plasma was mixed with 1 μl of Alexa Fluor 488–labeled human fibrinogen (10 μg/ml final; Thermo Fisher Scientific), 1.25 μl of CaCl 2 (200 mM stock; final 5 mM), and 2.5 μl of human thrombin (10 U/ml; Enzyme Research Laboratories, US) to initiate polymerization [thrombin (final 0.5 U/ml)].

Techniques: Injection, Saline

Journal: Brain

Article Title: Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer’s disease

doi: 10.1093/brain/awaf394

Figure Lengend Snippet: Elevated VEGF-A and EDN1 associated with cerebral hypoperfusion in early-stage Alzheimer's disease. Concentrations of ( A ) VEGF-A and ( B ) EDN1, measured by sandwich ELISA, in Braak tangle stage groups BS0–II, BSIII–IV and BSV–VI, across brain regions. Each data-point represents the average of a duplicate measurement in a single brain region. Z -scores were calculated to combine data from two independent cohorts. Mean ± standard error of the mean are shown. Correlation analysis between ( C ) VEGF-A and ( D ) EDN1 with the MAG:PLP1 ratio in the different brain regions. Solid linear regression lines are used to indicate brain regions with significant correlations, dashed lines indicate brain regions with non-significant relationships. Trigone is not shown as it did not fit within the range of the graph. * P < 0.05, ** P < 0.01, *** P < 0.001 indicate statistical strength of correlations within respective brain regions.

Article Snippet: The fibrinogen level was measured by commercially available sandwich ELISA (Human Fibrinogen ELISA kit, Cat. No. EH3057, Wuhan Fine Biological Technology Co.), as previously described., SDS brain tissue homogenates (1%) were diluted in PBS (1:125).

Techniques: Sandwich ELISA

Journal: Brain

Article Title: Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer’s disease

doi: 10.1093/brain/awaf394

Figure Lengend Snippet: CD31 levels are elevated in early-stage Alzheimer's disease and are related to MAG:PLP1 and VEGF-A . ( A ) CD31 levels, measured by ELISA, in Braak tangle stage groups BS0–II, III–IV and BSV–VI in the different brain regions. Each data-point represents the average of a duplicate measurement in a single brain region. Z -scores were used to combine data from two independent cohorts. ( B and C ) Correlation analysis between CD31 and VEGF-A, and MAG:PLP1 ratio, in the different brain regions. Solid linear regression lines are used to indicate brain regions with significant correlations, dashed lines indicate brain regions with non-significant relationships. Trigone is not shown as it did not fit within the range of the graph. * P < 0.05 and ** P < 0.01 indicate statistical strength of correlations within respective brain regions.

Article Snippet: The fibrinogen level was measured by commercially available sandwich ELISA (Human Fibrinogen ELISA kit, Cat. No. EH3057, Wuhan Fine Biological Technology Co.), as previously described., SDS brain tissue homogenates (1%) were diluted in PBS (1:125).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Brain

Article Title: Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer’s disease

doi: 10.1093/brain/awaf394

Figure Lengend Snippet: Mediators of angiogenesis are dysregulated in early-stage/intermediate pathology Alzheimer's disease. ( A and B ) Levels of endoglin (CD105), a marker of neoangiogenesis, measured first using the angiogenesis proteome profiler and then independently by commercial ELISA kit. Mean and standard error of the mean are shown. * P < 0.05, ** P < 0.01. ( C and D ) Levels of pro-angiogenic ( C ) and anti-angiogenic ( D ) mediators in early-stage/intermediate pathology [Braak tangle stage (BS) III–IV] (blue) and late-stage AD (BSV–VI) (red), relative to the levels in minimal pathology BS0–II cases.

Article Snippet: The fibrinogen level was measured by commercially available sandwich ELISA (Human Fibrinogen ELISA kit, Cat. No. EH3057, Wuhan Fine Biological Technology Co.), as previously described., SDS brain tissue homogenates (1%) were diluted in PBS (1:125).

Techniques: Marker, Enzyme-linked Immunosorbent Assay

Journal: iScience

Article Title: Integrating thermal liquid biopsy, clinical data, and mass spectrometry for early diagnosis and biomarker discovery in colorectal cancer

doi: 10.1016/j.isci.2026.114751

Figure Lengend Snippet: Differences in median protein concentrations according to the iTLB model (A) CRP levels in operated CRC patients, dichotomized by the standard cut-off threshold. (B) CRP levels in metastatic CRC patients, dichotomized by the standard cut-off threshold. (C) FGL1 levels in operated CRC patients, measured using ELISA, dichotomized by the standard cut-off threshold. Abbreviations: CRP, C-reactive protein; FGL1, fibrinogen-like protein-1; iTLB, intelligent thermal liquid biopsy.

Article Snippet: Additionally, FGL1 levels were measured using ELISA (Elabscience, E-El-H1667) in the 50 operated CRC patients analyzed by proteomics.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Journal of Clinical Laboratory Analysis

Article Title: Resolving Bivalirudin Interference on Fibrinogen Testing by the Use of Activated Carbon

doi: 10.1002/jcla.70184

Figure Lengend Snippet: Trends of results from four fibrinogen assays. As the concentration of bivalirudin increased, the APTT ratio increased accordingly. The fibrinogen results in each column were aligned with the corresponding APTT ratio listed above. The fibrinogen baseline values obtained from bivalirudin‐free samples (APTT ratio: 1.0) were listed in the first column. APTT, Activated partial thromboplastin time; NAHF, N Antiserum to Human Fibrinogen reagent.

Article Snippet: The fibrinogen assays used included HemosIL Fibrinogen‐C XL reagent (Clauss method) with a thrombin concentration of 35 NIH U/mL on ACL‐TOP analyzer (both from Werfen, USA); STA‐Fibrinogen reagent (Clauss method) with a thrombin concentration of 80 NIH U/mL on STA‐R Evolution analyzer (both from Diagnostica Stago, France); Dade Thrombin reagent (Clauss method, Siemens Healthcare, Germany) with a thrombin concentration of 100 NIH U/ml on CS‐5100 analyzer (Sysmex Corporation, Japan); and N Antiserum to Human Fibrinogen reagent (NAHF Immunoassay) on BN2 nephelometer analyzer (both from Siemens Healthcare, Germany).

Techniques: Concentration Assay

Journal: Journal of Clinical Laboratory Analysis

Article Title: Resolving Bivalirudin Interference on Fibrinogen Testing by the Use of Activated Carbon

doi: 10.1002/jcla.70184

Figure Lengend Snippet: SynthASil APTT (seconds) and HemosIL Fibrinogen‐C XL (g/L) results before and after the addition of activated carbon. After the addition of activated carbon, all SynthASil APTT and HemosIL Fibrinogen‐C XL results returned nearly to their baseline levels. APTT, activated partial thromboplastin time.

Article Snippet: The fibrinogen assays used included HemosIL Fibrinogen‐C XL reagent (Clauss method) with a thrombin concentration of 35 NIH U/mL on ACL‐TOP analyzer (both from Werfen, USA); STA‐Fibrinogen reagent (Clauss method) with a thrombin concentration of 80 NIH U/mL on STA‐R Evolution analyzer (both from Diagnostica Stago, France); Dade Thrombin reagent (Clauss method, Siemens Healthcare, Germany) with a thrombin concentration of 100 NIH U/ml on CS‐5100 analyzer (Sysmex Corporation, Japan); and N Antiserum to Human Fibrinogen reagent (NAHF Immunoassay) on BN2 nephelometer analyzer (both from Siemens Healthcare, Germany).

Techniques:

Journal: bioRxiv

Article Title: Fibrin Selective Alteplase with Improved Thrombolysis and Inhibition Resistance Engineered by Rational Design

doi: 10.64898/2026.01.19.700241

Figure Lengend Snippet: ( a ) Comparison of plasminogen activation enzymatic activities (dark solid bars) and their values in the presence of fibrinogen (hatched bars) and fibrin (light solid bars) stimulants. ( b ) Comparison of fibrinogen (solid bars) and fibrin (hatched bars) stimulation factors. The factors are defined as fibrin(ogen)-stimulated activity over non-stimulated activity ratios. ( c ) Comparison of fibrin selectivity factors. ( d ) Comparison of melting temperatures T m values, defining protein thermal stabilities. At T m, half of the protein molecules are unfolded. ( e ) Relative comparison of inhibition resistance towards plasminogen activator inhibitor-1 (PAI-1) calculated as a ratio of the IC50 value for a tested protein over the IC50 value for alteplase (reference benchmark protein). ( f ) Relative comparison of fibrin penetration potential calculated as a ratio of the fibrin dissociation constant ( K d) value for a tested protein over the fibrin K d value for alteplase (reference benchmark protein). Clinically used variants alteplase and tenecteplase are highlighted in blue and yellow, respectively. The variant Brnoteplase, which was selected for further in vitro and in vivo testing, is highlighted in green. Brnoteplase exhibited superior fibrin stimulation, fibrin selectivity, PAI-1 inhibition resistance, and penetration potential. Please note the logarithmic scale of the x-axis in ( a ), ( b ), and ( c ). The bars represent mean values and the whiskers correspond to standard errors.

Article Snippet: In the case of fibrin stimulation, small fibrin clots were formed in a microplate well of a black clear bottom 96-well plate by mixing 8 μL of human fibrinogen (HYPHEN BioMed) with 2 μL of human thrombin (Sigma-Aldrich).

Techniques: Comparison, Activation Assay, Activity Assay, Inhibition, Variant Assay, In Vitro, In Vivo